Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (2041)	7/21/1998 11:19:00 AM
From: BWAC	Read Replies (1) \| Respond to of 2553

Yikes!! Whats this 4 1/4 stuff. Thank goodness for the positive article on Epicel. We know that works very well and they are improving the process. Only 14 days now to culture enough skin to cover the entire body from one 2 square inch sample. Carticel seems to be ramping up well. Insurance companies are starting to accept the procedure. Doctors being trained. Could the stock price problem be related to Neurocell for Parkinsons? Frankly I've always thought that implanting fetal porcine cells into the brain was a little far fetched and would be hard to get accepted by patients and doctors. But for most long term Parkinsons the other available drugs simply do not work after a while. And they really start to affect the mind with short term memory loss, confusion, hallucinations, depression, etc. All this leads eventually to more medication to alleviate these specific problems. And the patients have to take increasingly larger doses of Parkinsons medication over time. I think I lost my point. Anyway it was that something new that works for Parkinsons might actually be accepted no matter how strange. Considering all this. I'm going to buy at 4 1/4 if it gets filled. I feel the downside is little (only $4) and upside large. GENZ will not let GENZL fail. They own a lot too. They would exercise the buyback option soon if this price falls much farther.